FDA 483 - Octapharma S.A.S.
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Octapharma S.A.S. in Lingolsheim, France, a blood product manufacturer, revealed significant deficiencies in their quality system. The firm was cited for inadequate investigations into unexplained discrepancies, untimely implementation of corrective and preventive actions (CAPAs), and incomplete process validation. Additionally, deficient procedures and a lack of change control for recurring human error deviations were observed, indicating a need for improved manufacturing controls.
- Company
- Octapharma S.A.S.
- Product Type
- Biologics
ID · 352cd8a6-3db9-45e7-88cd-5ac5d080427d